-
1 Comment
Kadmon Holdings, Inc is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 94.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.0.
Kadmon Holdings, Inc's total revenue sank by 86.0% to $615K since the same quarter in the previous year.
Its net income has dropped by 137.6% to $-28M since the same quarter in the previous year.
Finally, its free cash flow fell by 63.9% to $-27M since the same quarter in the previous year.
Based on the above factors, Kadmon Holdings, Inc gets an overall score of 1/5.
ISIN | None |
---|---|
Industry | Biotechnology |
Sector | Healthcare |
CurrencyCode | EUR |
Exchange | F |
Beta | 1.12 |
---|---|
PE Ratio | None |
Market Cap | 1B |
Target Price | 12.1 |
Dividend Yield | None |
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. As of November 9, 2021, Kadmon Holdings, Inc. operates as a subsidiary of Sanofi.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KDF.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024